NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 7 Jan 2019 (#1)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit **www.grants.nih.gov** or **www.sun.ac.za/RDSfunding** (current & archive).*

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

***Contact: RGMO Pre-Awards** cdevries@sun.ac.za*

Important Notices

- **Findings of Research Misconduct (NOT-OD-19-048) & (NOT-OD-19-049)**
- **Notice of Interest in Advancing Research in Acute Flaccid Myelitis and Guillain-Barre Syndrome (NOT-NS-19-029)**
- **NIH Implementation of the Final Rule on the Federal Policy for the Protection of Human Subjects (Common Rule) (NOT-OD-19-050)**

1. NEI Audacious Goals Initiative: Preliminary Studies for Translation-Enabling Models of the Visual System (R21 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-EY-19-001) **Type: R21**
Application Due Date: March 8, 2019. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for short-term, proof-of-principle research projects that will provide preliminary data for a future FOA aimed at the development of new models that emulate human visual system anatomy, physiology and disease processes. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement and/or regenerative therapy. Using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA.
Budget: The NEI intends to commit $4-5M (total costs) in FY 2019 to fund 10-15 awards. Applicants may request up to $200,000 in direct costs (exclusive of consortium facilities and administrative costs) for the 1-year project.

2. Revision Application for Implementation Research to Inform and Enhance PEPFAR HIV Pre-exposure Prophylaxis (PrEP) Delivery (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-MH-19-425) **Type: R01**
Application Due Date: February 18, 2019. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The National Institute of Mental Health (NIMH), in collaboration with the Office of the U. S. Global AIDS Coordinator (OGAC), is soliciting revision applications for implementation science research that will inform delivery and scale-up of pre-exposure prophylaxis (PrEP) at President's Emergency Plan for AIDS Relief (PEPFAR) sites.
Revision applications should include expansion of existing, or proposal of new project or projects. Revision applications may not request support beyond the end date of the parent R01 award.
Budget: NIMH intends to commit $2,000,000 in FY 2019 to fund 10 awards. Application budgets are limited to no more than $150,000 direct costs per year and must reflect the actual needs of the proposed studies. The project and budget period must be for one year and be within the currently approved project period for the existing parent award.

3. Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-19-111) **Type: R21**
(PA-19-112) **R01**

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiovascular risk prior to treatment and integrate evidence-based cancer treatment regimens with cardiovascular screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac and/or vascular specific common terminology criteria for adverse events (CTCAE).
Budget: R21 - The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in a single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-19-113) **Type: R01**
Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.
Budget: Application budgets are limited to $400,000 Direct Costs per year. The budget should reflect the actual needs of the proposed project. The maximum project period is 5 years. The scope of the proposed project should determine the project period.

5. End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-19-136) **Type: R01**
Application Due Date: Standard dates & Standard AIDS dates Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***